KRTX - Karuna Therapeutics closes ~$863M underwritten public offering
- Clinical-stage biopharmaceutical company Karuna Therapeutics ( NASDAQ: KRTX ) closed a previously-announced upsized underwritten public offering of ~4M shares, with the underwriters exercising in full their option to purchase an additional 523K shares at $215 per share.
- The company received gross proceeds of ~$863M.
- Goldman Sachs & Co. LLC and J.P. Morgan acted as joint book-running managers, while Jefferies was a book-running manager.
- Stifel, Guggenheim Securities and RBC Capital Markets acted as lead managers, and JMP Securities, a Citizens Company, and Wedbush PacGrow acted as co-managers.
- Shares were trading -0.67% post-market.
- Source: Press Release
For further details see:
Karuna Therapeutics closes ~$863M underwritten public offering